| Name | Title | Contact Details |
|---|
Med Depot is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Biotronic NeuroNetwork is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MISSION is the first and only line of athlete-engineered products designed to enhance performance in training and competition. Co-founded in 2009 by a premier group of world-class athletes including Serena Williams, Dwyane Wade, Sergio Garcia, David Wright, Reggie Bush and Mia Hamm, MISSION boasts more than 25 high-performance product innovations and is sold in nearly 20,000 stores across the U.S. MISSION works with its world-renowned athletes, doctors and scientists to engineer products that help athletes prepare, perform and rehab from training or competition.
At Bayshore, we believe in creating special moments for our clients each and every day, whether at the bedside, on the phone or in the clinic. These moments touch the lives of our clients and our employees, and they guide the way we run our business. These moments inspire, change and encourage us. They are what we call the Bayshore difference. Bayshore HealthCare is one of the country`s leading providers of home and community health care services and is a Canadian-owned company.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.